Quality of Life in Patients With Hemorrhagic Telangiectasia
Launched by UNIVERSITY HOSPITAL, ESSEN · Feb 7, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • knowledge of german language
- • Age above 17 years
- • capable of giving consent
- • Diagnosis of HHT (Curaçao criteria or genetic testing)
- Exclusion criteria:
- • -Individuals not meeting the inclusion criteria.
About University Hospital, Essen
The University Hospital Essen is a leading academic medical center dedicated to advancing healthcare through innovative research and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical disciplines to facilitate cutting-edge studies aimed at improving patient outcomes. With a commitment to scientific excellence and patient safety, the University Hospital Essen collaborates with a network of researchers and healthcare professionals to explore new therapies and treatment modalities, contributing significantly to the field of medicine and enhancing the overall quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, Nrw, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported